Corvus Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per S...



3. Net Loss per Share



 



The following table shows the calculation of net loss per share (in thousands, except share and per share data):



 









































































































 




 




 




 




 




 




 




 




 




 




Three Months Ended




 




 




 




March 31, 




 




 




    




2020




    




2019




    




Numerator:




 




 




  




 




 




  




 




Net loss - basic and diluted




 




$




(12,935)




 




$




(11,643)




 




Denominator:




 




 




 




 




 




  




 




Weighted average common shares outstanding




 




 




29,411,233




 




 




29,326,075




 




Less: weighted average common shares subject to repurchase




 




 




 —




 




 




(33,940)




 




Weighted average common shares outstanding used to compute basic and diluted net loss per share




 




 




29,411,233




 




 




29,292,135




 




Net loss per share, basic and diluted




 




$




(0.44)




 




$




(0.40)




 




 



Weighted average common shares outstanding for the three months ended March 31, 2020 include 1,458,000 shares of common stock issuable on the conversion of pre-funded warrants described in Note 1.



 



The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti‑dilutive effect:



 

























































 




 




 




 




 




 




 




 




Three Months Ended




 




 




 




March 31, 




 




 




    




2020




    




2019




    




Common stock subject to repurchase




 




 —




 




27,073




 




Outstanding options




 




5,719,820




 




4,040,925




 




Total shares of common stock equivalents




 




5,719,820




 




4,067,998




 




 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh